Is the Future of Statins Aligned with New Novel Li

Authors: Binh An P Phan Peter P Toth

Publish Date: 2013/01/10

Volume: 15, Issue: 2, Pages: 300-

PDF Link

Abstract

Dyslipidemia is an established risk factor for the development of atherosclerotic cardiovascular disease Statin therapy has been proven in a number of clinical trials to lower the risk of acute cardiovascular events and is the mainstay of cholesterol treatment Despite current optimal treatment for dyslipidemia many patients fail to reach adequate cholesterol treatment goals and remain at a significantly increased risk of cardiovascular events Given this residual risk there is a critical need for additional lipid therapies that could augment the ability of statins to lower the burden of atherogenic lipoproteins and in some cases raise levels of highdensity lipoproteins A number of novel lipidaltering therapies have been developed and are currently in clinical trials In this review we discuss these promising therapies which include PCSK9 inhibitors apolipoprotein B antisense oligonucleotides microsomal transfer protein inhibitors thyroid mimetics and cholesteryl ester transfer protein inhibitors Although statin therapy is the current recommended primary treatment for dyslipidemia emerging novel agents may become adjuvant therapies in the treatment of atherosclerotic heart disease

Keywords: